Galectin Therapeutics (GALT) Competitors $2.78 +0.06 (+2.21%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GALT vs. ENOB, LUMO, KIN, ANAB, ORIC, ABUS, DNTH, PHAT, EXAI, and IMNMShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Enochian Biosciences (ENOB), Lumos Pharma (LUMO), Kindred Biosciences (KIN), AnaptysBio (ANAB), ORIC Pharmaceuticals (ORIC), Arbutus Biopharma (ABUS), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), Exscientia (EXAI), and Immunome (IMNM). These companies are all part of the "medical" sector. Galectin Therapeutics vs. Enochian Biosciences Lumos Pharma Kindred Biosciences AnaptysBio ORIC Pharmaceuticals Arbutus Biopharma Dianthus Therapeutics Phathom Pharmaceuticals Exscientia Immunome Galectin Therapeutics (NASDAQ:GALT) and Enochian Biosciences (NASDAQ:ENOB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability. Which has stronger earnings & valuation, GALT or ENOB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$41.07M-$0.73-3.81Enochian BiosciencesN/AN/A-$113.43MN/AN/A Does the media refer more to GALT or ENOB? In the previous week, Galectin Therapeutics had 8 more articles in the media than Enochian Biosciences. MarketBeat recorded 8 mentions for Galectin Therapeutics and 0 mentions for Enochian Biosciences. Galectin Therapeutics' average media sentiment score of 0.07 beat Enochian Biosciences' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Galectin Therapeutics Neutral Enochian Biosciences Neutral Which has more volatility & risk, GALT or ENOB? Galectin Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Enochian Biosciences has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Does the MarketBeat Community favor GALT or ENOB? Galectin Therapeutics received 347 more outperform votes than Enochian Biosciences when rated by MarketBeat users. CompanyUnderperformOutperformGalectin TherapeuticsOutperform Votes34759.32% Underperform Votes23840.68% Enochian BiosciencesN/AN/A Do analysts recommend GALT or ENOB? Galectin Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 295.68%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Galectin Therapeutics is more favorable than Enochian Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enochian Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in GALT or ENOB? 11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Enochian Biosciences shares are owned by institutional investors. 52.7% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 21.7% of Enochian Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is GALT or ENOB more profitable? Galectin Therapeutics' return on equity of 0.00% beat Enochian Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -163.15% Enochian Biosciences N/A -154.69%-130.66% SummaryGalectin Therapeutics beats Enochian Biosciences on 10 of the 12 factors compared between the two stocks. Ad Brownstone ResearchMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$174.47M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-3.8111.10105.1417.83Price / SalesN/A362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book-1.8410.377.096.50Net Income-$41.07M$153.60M$119.65M$226.22M7 Day Performance0.36%4.60%2.25%4.03%1 Month Performance7.75%-6.29%-2.33%4.92%1 Year Performance36.95%33.41%33.98%29.30% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics1.7197 of 5 stars$2.78+2.2%$11.00+295.7%+36.9%$174.47MN/A-3.819Analyst UpgradeENOBEnochian BiosciencesN/AN/AN/AN/A$40.80MN/A0.0022Gap UpLUMOLumos Pharma2.621 of 5 stars$4.31-0.5%$8.63+100.1%+39.9%$37.28M$2.05M-1.0030High Trading VolumeKINKindred Biosciences0.8513 of 5 stars$9.25flatN/A+0.0%$420.52M$42.16M-16.8263ANABAnaptysBio2.5319 of 5 stars$22.27+5.2%$54.64+145.3%+56.8%$677.65M$57.17M-3.66100ORICORIC Pharmaceuticals4.2201 of 5 stars$9.59+5.2%$18.29+90.7%+31.4%$676.77MN/A-5.3380Gap UpABUSArbutus Biopharma2.6471 of 5 stars$3.51+1.4%$5.50+56.7%+90.8%$665.12M$6.74M-8.1273Analyst ForecastDNTHDianthus Therapeutics1.3492 of 5 stars$22.34+10.2%$46.43+107.8%+96.7%$661.20M$5.37M-8.9480PHATPhathom Pharmaceuticals2.628 of 5 stars$9.34-1.2%$22.50+140.9%+33.6%$646.16M$26.27M-1.64110EXAIExscientia2.2455 of 5 stars$4.84flat$7.00+44.6%N/A$632.93M$25.60M-3.21280News CoverageIMNMImmunome1.86 of 5 stars$9.82+4.2%$28.83+193.6%+23.7%$612.96M$14.02M-1.2140 Related Companies and Tools Related Companies ENOB Alternatives LUMO Alternatives KIN Alternatives ANAB Alternatives ORIC Alternatives ABUS Alternatives DNTH Alternatives PHAT Alternatives EXAI Alternatives IMNM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GALT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts